Edition:
India

Aslan Pharma Updates Timelines For Clinical Trial Of Varlitinib In Biliary Tract Cancer In China


Monday, 17 Sep 2018 

Sept 17 (Reuters) - Aslan Pharmaceuticals Ltd <6497.TWO>::ASLAN PHARMACEUTICALS PROVIDES UPDATE ON TIMELINES FOR CLINICAL TRIAL OF VARLITINIB IN BILIARY TRACT CANCER IN CHINA.ASLAN PHARMACEUTICALS - AGREED THAT A PROTOCOL AMENDMENT SHOULD BE SUBMITTED TO TO MODIFY ENROLMENT CRITERIA.ASLAN PHARMACEUTICALS - AGREED THAT PROTOCOL AMENDMENT SHOULD BE SUBMITTED TO ENSURE STUDY WILL PROVIDE ACCURATE EVALUATION OF VARLITINIB'S EFFICACY.ASLAN PHARMACEUTICALS LTD - REVIEW AND IMPLEMENTATION OF VOLUNTARY AMENDMENT IS EXPECTED TO TAKE APPROXIMATELY 4 MONTHS.ASLAN PHARMACEUTICALS LTD - WILL CONTINUE TO RECRUIT PATIENTS INTO STUDY AND PROVIDE A FURTHER UPDATE ON STUDY TIMELINES IN EARLY 2019.ASLAN - PATIENTS ENROLLED IN SECOND LINE APPEAR TO HAVE PERFORMED SIGNIFICANTLY WORSE, PRIOR TO RECRUITMENT, IN FIRST LINE SETTING VERSUS GLOBAL STUDIES.ASLAN PHARMACEUTICALS LTD - DO NOT SEE ANY IMPACT ON OTHER ONGOING PLACEBO-CONTROLLED STUDIES. 

Company Quote

1.96
-0.06 -2.97%
2:29am IST